Login
Companies $BMY
$62.93 +$0.00 (0.0%) After hours
BRISTOL MYERS SQUIBB CO logo

BRISTOL MYERS SQUIBB CO

bms.com

What Do They Do?

Develops, manufactures and sells prescription medicines for serious diseases, supplying wholesalers, distributors and specialty pharmacies.

How Do They Make Money?

Customers buy medicines through wholesalers, distributors and specialty pharmacies; orders are generally filled within a few days and payment terms are typically 30 to 90 days. Alliance and licensing income can include upfront and milestone payments, royalties on partner sales, and payments for product supply.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Net product sales
Sold outright

97%
FY2022: 97%
Alliance revenues
Licensed
0.9%
FY2022: 1.6%
Other revenues
Licensed
2.1%
FY2022: 1.6%

Who Are Their Customers?

Sells mainly through wholesalers, distributors and specialty pharmacies, with smaller sales to retailers, hospitals, clinics, government agencies and patients; it has also announced direct-to-patient offerings for several U.S. products.

Do Revenues Turn Into Profits?

Yes. It kept 15 cents of every revenue dollar as net income in FY2025 and turned 27 cents into free cash flow.

Operating income, FY2025
19% of revenue
▲ Turned profitable vs FY2024 (−$8.4B, −17%)
Net income, FY2025
15% of revenue
▲ Turned profitable vs FY2024 (−$8.9B, −19%)
Free cash flow, FY2025
27% of revenue
▼ −8% vs FY2024 ($13.9B, 29%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +7%
vs $12.2B in Q3 FY2025
Net income
▼ −2%
vs $2.2B in Q3 FY2025
Net product sales share of revenue vs 97.0% in Q3 FY2025
  • Jul 30, 2026 Raised its full-year outlook Revenue guidance rose to ~$49.0 billion to $50.0 billion, and non-GAAP EPS guidance to $6.75 to $7.00.

Flat. Revenue was $48.2B in FY2025, about the same as the $46.4B of FY2021.

Broader treatment technologies The product platform description expands beyond small-molecule drugs, biologics and CAR-T therapies to include protein degraders, antibody-drug conjugates and radiopharmaceutical therapeutics.

Revenue over time
Net product sales Alliance revenues Other revenues
$50B$25B$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support